ArticleScientific reports2026
Quantification of overall tumor burden using longitudinal magnetic resonance imaging improves response assessment in orthotopic murine hepatocellular carcinoma models.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related death worldwide. Mirroring the complexity of human HCC with its underlying liver disease requires multilocular orthotopic tumor models in mice, where objective tumor quantification in vivo is challenging, especially longitudinally. We investigated magnetic resonance imaging (MRI) to noninvasively quantify orthotopic HCC in an immunotherapy setting. Orthotopic HCCs were induced in diethylnitrosamine (DEN)-injected mice with either CCl4-induced hepatic fibrosis or dietary metabolic dysfunction-associated steatotic liver disease (MASLD) to mirror the most frequent etiologies. Growth kinetics over the course of immune checkpoint inhibitor treatment with anti-Programmed Death Ligand 1 (αPD-L1) were modeled by measuring the overall tumor burden (OTB) using MRI and compared to untreated animals. Tumor parameters, such as tumor volume, liver weights at sacrifice and largest tumor diameter were analyzed. We demonstrate that MRI is a reliable imaging tool for both pretreatment tumor confirmation as well as the longitudinal quantification of overall tumor burden under investigational treatment. While measuring only the largest tumor diameter yielded significant differences between αPD-L1-treated animals and untreated controls in the long-term setting, these trends in tumor response were not confirmed by MRI-based OTB measurement. In MASLD-HCC, tumors did not respond to PD-L1 blockade, thus confirming the OTB data and reflecting the immunotherapy resistance observed in the human setting and highlighting the translational relevance of the model. Orthotopic fibrosis-HCC and MASLD-HCC mouse models can be enhanced through the longitudinal use of MRI while reducing endpoints and animal numbers. The DEN-CCl4 and DEN-Western Diet models mirror the αPD-L1 response from the human setting and require OTB measurement, because largest diameters may underestimate the total tumor mass in orthotopic HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.